In this interview, Prof. Barrios answers the following questions:

• What is the rationale for including targeted therapies in the treatment paradigm for HR+/HER2– early breast cancer?
• How are targeted systemic therapies for HR+/HER2– early breast cancer currently integrated into clinical practice guidelines?
• In light of the approved targeted systemic therapies for HR+/HER2– early breast cancer, what unmet needs remain?

Prof. Carlos Barrios is the director of clinical research and oncologist at the Latin American Cooperative Oncology Group (LACOG) and the director and principal investigator of the Oncology Research Center at Hospital São Lucas, Pontifica Universidade Catolica do Rio Grande do Sul (PUCRS) in Porto Alegre, Brazil. read more

Prof. Carlos Barrios discloses: Advisory board and consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eisai, GSK, Lilly, MSD, Novartis, Pfizer, Roche/Genentech, Sanofi and Zodiac. Grants/research support (to the institution) from Amgen, AstraZeneca, Aveo Oncology, BioNTech, BMS, Daiichi Sankyo, Dizal Pharma, Exelixis, Fortrea, Gilead Sciences, GSK, ICON, IQVIA, Janssen, Labcorp, Lilly, Medpace, MSD, Novartis, Novocure, Nuvisan, OBI Pharma, Parexel, Pfizer, PharmaMar, PPD, PSI, Regeneron, Roche, Samsung, Sandoz, Sanofi, Seagen, Servier, Stemline, Syneos Health, Takeda, Taiho, Tolmar, TRIO and Worldwide. Ownership or stocks from MEDSir and Tummi.

In this interview, Prof. Dr. med. Fasching answers the following questions:

• What is the current status of CDK4/6 inhibitors for patients with HR+/HER2– early breast cancer?
• What do the latest pivotal trial data tell us about the efficacy of CDK4/6 inhibitors in patients with HR+/HER2– early breast cancer?
• What key safety considerations should be taken into account in light of the pivotal trials for CDK4/6 inhibitors in patients with HR+/HER2– early breast cancer?
• How can CDK4/6 inhibitors address the unmet needs of patients with HR+/HER2– early breast cancer?

Prof. Dr. med. Fasching is currently the head of the Clinical Trials Unit at Women’s Clinic of the University Hospital Erlangen, is the coordinator to the Breast Cancer Center and Gynaecological Oncology Center, and head of the biomaterial bank. He is also an associate professor of gynaecology, obstetrics and translational medicine at the Friedrich-Alexander University Erlangen-Nuremberg and the National Center for Tumour Diseases WERA in Erlangen, Germany. read more

Prof. Dr. med. Peter Fasching discloses: Advisory board or consultancy fees from Agendia, AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Menarini, MSD, Mylan, Novartis, Pfizer, Roche, SeaGen and Veracyte. Speaker’s bureau fees from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, GuardantHealth, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, SeaGen and Veracyte. Grants/research support (to the institution) from BioNtech, Cepheid and Pfizer.

In this interview, Dr Pernas answers the following questions:

• What role does risk stratification play when considering treatment with CDK4/6 inhibitors for patients with HR+/HER2– early breast cancer?
• How would you advise selecting the optimal CDK4/6 inhibitor for eligible patients with HR+/HER2– early breast cancer?
• In your opinion, what are some key considerations for maximizing the potential of CDK4/6 inhibitors in patients with HR+/HER2– early breast cancer?

Dr Sonia Pernas is head of the Breast Cancer Unit at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), in Barcelona, Spain, and is an assistant professor at the University of Barcelona. read more

Dr Sonia Pernas discloses: Advisory board or consultancy fees from AstraZeneca, Daiichi Sankyo, Lilly, Pfizer and SeaGen. Speaker’s bureau fees from AstraZeneca–Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer and Roche. Travel grants from AstraZeneca, Gilead, Novartis, Pfizer and Roche.